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Abstract 
The present study aimed at investigating the weak cation magnetic separation technology and matrix‑assisted laser 
desorption ionization‑time of flight‑mass spectrometry (MALDI‑TOF‑MS) in screening serum protein markers of 
osteopenia from ten postmenopausal women and ten postmenopausal women without osteopenia as control group, 
to find a new method for screening biomarkers and establishing a diagnostic model for primary type I osteoporosis. 
Serum samples were collected from postmenopausal women with osteopenia and postmenopausal women with 
normal bone mass. Proteins were extracted from serum samples by weak cation exchange magnetic beads technol‑
ogy, and mass spectra acquisition was done by MALDI‑TOF‑MS. The visualization and comparison of data sets, statisti‑
cal peak evaluation, model recognition, and discovery of biomarker candidates were handled by the proteinchip data 
analysis system software(ZJU‑PDAS). The diagnostic models were established using genetic arithmetic based support 
vector machine (SVM). The SVM result with the highest Youden Index was selected as the model. Combinatorial Peaks 
having the highest accuracy in distinguishing different samples were selected as potential biomarker. From the two 
group serum samples, a total of 133 differential features were selected. Ten features with significant intensity differ‑
ences were screened. In the pair‑wise comparisons, processing of MALDI‑TOF spectra resulted in the identification 
of ten differential features between postmenopausal women with osteopenia and postmenopausal women with 
normal bone mass. The difference of features by Youden index showed that the highest features had a mass to charge 
ratio of 1699 and 3038 Da. A diagnosis model was established with these two peaks as the candidate marker, and the 
specificity of the model is 100 %, the sensitivity was 90 % by leave‑one‑out cross validation test. The two groups of 
specimens in SVM results on the scatter plot could be clearly distinguished. The peak with m/z 3038 in the SVM model 
was suggested as Secretin by TagIdent tool. To provide further validation, the secretin levels in serum were analyzed 
using enzyme‑linked immunosorbent assays that is a competitive inhibition enzyme immunoassay technique for the 
in vitro quantitative measurement of secretin in human serum.
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Background
Osteoporosis is a skeletal disorder characterized by low 
bone mass and bone microstructure degeneration. With 
the advent of the aging society, the incidence rate of oste-
oporosis is rising quickly, osteoporosis has become a seri-
ous threat to the health of the elderly (Consensus NIH 
2001; Czerwiński et al. 2006).
Before people develop osteoporosis, they have a con-
dition called osteopenia. Osteopenia was firstly defined 
by the World Health Organization (WHO) in June 
1992(Knapp et al. 2004). Osteopenia usually doesn’t cause 
any symptoms. Losing bone mass is not painful. Broken 
bones or fractures can occur, but these problems tend to 
happen after osteoporosis has developed. Osteopenia is 
not a disease, but if you meet the criteria for osteopenia, 
you are at higher risk for developing osteoporosis. Early 
diagnosis and treatment can prevent osteopenia from 
becoming osteoporosis.
The bone mineral density (BMD) measurement is use-
ful in clinical application on the diagnosis of osteoporosis 
and the prediction of fracture in elderly women, but it is a 
lagging-not an early-indicator. Dual-energy X-ray absorp-
tiometry (DXA) is currently recognized as gold standard 
of osteopenia and osteoporosis diagnosis (Kanis et  al. 
2013). Although DXA measurement is the gold standard, 
but early symptom of osteopenia or osteoporosis is not 
easy to detect, so that many patients with osteopenia or 
osteoporosis are often found after the first fracture. BMD 
does not reflect the change of bone matrix, bone turno-
ver and bone strength. BMD could not accurately predict 
the risk of bone fractures (Oei et al. 2013).
With the completion of human genome project, the 
post genomic era is coming. We can rapidly screen the 
specific biomarkers of the disease by proteomics tech-
nologies (Ray et  al. 2011), clarify the pathogenesis of 
the disease, and explore new methods of preventing and 
treatment.
Magnetic beads with large separation capacity has been 
widely used in cancer research using serum samples and 
beads based technology enrichment are high-through-
put, simple and quick to operate (Wu et  al. 2012; Fan 
et al. 2012).
Matrix-assisted laser desorption/ionization-time of 
light-mass spectrometry (MALDI-TOF-MS) is a recently 
emerged proteomics method, with the potential to detect 
various clinical samples, such as serum, urine, pleural effu-
sion, ascites and a number of secretions (Zhang et al. 2012; 
Zheng et al. 2011). Analysis of the serum samples proteome 
may detect changes that reflect bone issues with patho-
logical processes in the bone turnover. Furthermore, serum 
samples are simply and non-invasively obtained. Thus, pro-
teomic analysis of serum samples may be a useful tool in 
the prediction, early diagnosis, treatment monitoring, and 
prognostic assessment of osteopenia patients. Weak cat-
ion exchange magnetic beads (MB-WCX) combined with 
MALDI-TOF-MS is one such approach that offers a unique 
tool for profiling of proteins, but this approach has not 
been used in the osteopenia area.
In this study, we introduced a developed optimal 
method of mass spectrometry-based technology, weak 
cation magnetic separation technology combined with 
MALDI-TOF-MS, searching for efficient serum protein 
biomarkers, attempting to predict Molecular mecha-
nisms of osteopenia, thus reducing the uncertainties 
and potential risks in the primary type I osteoporosis 
patients. In this study, we developed a strategy for screen-
ing serum proteins <20 kDa to analyze serum profiles and 
find potential biomarkers for the osteopenia.
Results
Statistical analysis of baseline data
There are no statistically significant difference (P > 0.05) 
between comparisons of subjects of age, weight, height, 
and duration of menopause and it’s comparable. The 
results were shown in Table 1.
Detection of differential features
By application of WCX combined with MALDI-TOF MS, 
we analyzed the proteomic profiles between two groups. 
The serum samples contain a high diversity of proteins. A 
total of 133 peaks in the molecular weight range of 1000–
20,000 Da were identified between the two groups in this 
study. The results are shown in Fig. 1.
Discriminative ability of representative differential features
Genetic algorithm (GA) and support vector machine 
(SVM) embedded in ZJU-PDAS software (Qiu et  al. 
2009) were used to establish cross-validated classification 
model for distinguishing osteopenia group from normal 
bone mass group. Although there were 10 peaks show-
ing different peaks between two groups (P < 0.05), only 
two (1699 and 3038 Da) of them showed statistically sig-
nificant differences in further analysis by Youden Index 
(Fluss et  al. 2005; Bantis et  al. 2014). The peak mass, P 
values, average peak intensity, and standard deviation 
(SD) of the four peaks were shown in Table 2. The peaks 
analyzed to generate a classification model were based 
on the two peaks with m/z of 1699 and 3038 Da in Fig. 2. 
In the optimal SVM model, the two peaks with molecu-
lar weight of 1699 Da were upregulated in patients with 
osteopenia and 3038 Da were downregulated. 
Development of diagnostic models and evaluation of their 
diagnostic accuracy
The top peaks of 1699 and 3038  Da could distinguish 
serum samples between osteopenia group from normal 
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bone mass group effectively. The results are shown in 
Table 3. The serum proteomic model, based on a group 
of 2 peaks, accurately recognized osteopenia group from 
normal bone mass group. A diagnosis model was estab-
lished with these two peaks as the candidate marker. Two 
groups of specimens could be clearly distinguished in the 
SVM result scatter plot. The result is shown in Fig. 3.
Validation of the candidate biomarker secretin using ELISA
The peak with m/z 3038 in the SVM model was suggested 
as Secretin by TagIdent tool. Enzyme-linked immuno-
sorbent assays (ELISA) is commonly used in clinical set-
tings, for the direct validation and quantification of the 
identified Secretin, the ELISA technique was used.
The 80 serums for ELISA validation from 40 osteope-
nia patients and 40 postmenopausal women with nor-
mal bone mass, specifically (Table 4). Statistical analysis 
showed that there is no bias for age, weight, height, and 
duration of menopause between the osteopenia group 
and healthy control.
The secretin concentrations of postmenopausal women 
with normal bone mass and osteopenia patients differed 
significantly (P  <  0.05). Result showed that the normal 
bone mass group had significantly higher secretin signals 
Table 1 Comparisons of clinical features of patients
Data shown are mean ± standard deviation
Groups Age (years) Weight (kg) Height (cm) Duration of  
menopause (years)
Osteopenia (n = 10) 56.32 ± 3.61 53.16 ± 5.36 160.50 ± 10.53 5.26 ± 2.61
Normal bone mass (n = 10) 55.00 ± 3.48 52.24 ± 3.97 161.48 ± 11.00 4.76 ± 1.57
t 0.83 0.44 0.20 0.52
P values >0.05 >0.05 >0.05 >0.05
















Fig. 1 Detection of differential features. The spectrum shown in Fig. 1 is a composite spectrum from all spectra obtained from all individual patients
Table 2 Statistics of significantly different expressed peak 
intensities to distinguish patients from controls
Data shown are mean ± standard deviation




P vaules Expression 
change
1699 299.04 ± 140.72 164.32 ± 105.04 0.037 ↑
3038 383.78 ± 332.46 649.97 ± 236.04 0.014 ↓
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Fig. 2 Discriminative ability of representative differential features. The top 2 discriminating peaks of 1699 and 3038 Da could distinguish serum 
samples between osteopenia and postmenopausal women with normal bone mass effectively. a Displayed the peaks of 3038 Da. b Displayed the 
peaks of 1699 Da
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than that of osteopenia group. The result is shown in 
Table  5. As expected, the results of ELISA validation is 
consistent with the MALDI-TOF MS results.
Discussion
Although some progress has been made in the analysis 
of osteopenia disease, and to date there was no previous 
study to describe the application of MB-WCX combined 
with MALDI-TOF-MS technology in serum samples 
in osteopenia. In the present study, our results demon-
strated that a diagnostic model was constructed success-
fully, which had discriminated postmenopausal women 
with osteopenia and postmenopausal women with nor-
mal bone mass.
In recent years with the development of proteom-
ics technology, a variety of biological markers in clini-
cal been widely applied (Siew et  al. 2011; Hampel et  al. 
2014; Rousseau and Garnero 2012). Biological markers 
play an important role in disease diagnosis. Using serum 
proteomics technology (Ray et al. 2011) (Nanjappa et al. 
2013) to find important molecular markers provides an 
effective method for the clinical diagnosis of the disease.
Currently, the commonly used serum bone markers, 
such as total Procollagen I N Terminal Peptide (PINP) 
(Pollmann et  al. 2007), the carboxy-terminal cross-link-
ing telopeptide of type I collagen (β-CrossLaps) (Chubb 
et al. 2015), N-terminal osteocalcin and 25-hydroxyvita-
min D3 reflect the changes of bone metabolism. How-
ever, some bone turnover markers have a low sensitivity 
Table 3 Diagnostic accuracy of  different classification 
models in the training set










Osteopenia 9 1 10 90 10
Normal bone 
mass
0 10 10 100 0




















SVM Result Scatter Plot
Osteopenia group 
Normal bone mass group
Fig. 3 Development of diagnostic models and evaluation of their diagnostic accuracy. SVM result scatter plot, each point represents a sample, 
x-axis a main component; y-axis the predicted value. Mass/change means m/z
Table 4 Comparisons of Clinical features of patients in the ELISA validation
Data shown are mean ± standard deviation
Groups Age (years) Weight (kg) Height (cm) Duration of  
menopause (years)
Osteopenia (n = 40) 56.56 ± 3.78 54.09 ± 4.98 161.43 ± 10.29 5.34 ± 2.56
Normal bone mass (n = 40) 56.10 ± 3.50 53.29 ± 3.85 162.52 ± 10.58 4.95 ± 1.63
t 0.56 0.80 0.47 0.81
P values >0.05 >0.05 >0.05 >0.05
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and specificity in the early diagnosis of osteopenia that 
did not meet requirements of non-invasive and specific 
early diagnosis of osteopenia in the clinical practice 
(Bhattacharyya et al. 2008).
In this study, we screened 2 discriminating peaks of 
1699 and 3038 Da which had distinguished serum sam-
ples between postmenopausal women with osteopenia 
and postmenopausal women with normal bone mass 
effectively. The serum proteomic model, based on a 
group of 2 peaks, accurately recognized postmeno-
pausal women with osteopenia and postmenopausal 
women with normal bone mass with a sensitivity of 
90  % and a specificity of 100  % by Leave-one-out test 
verification. The peak with m/z 3038 in the SVM model 
was suggested as Secretin by TagIdent tool. Results also 
showed that the normal bone mass group had signifi-
cantly higher secretin signals than that of osteopenia 
group by ELISA. Secretin was known to be produced 
in response to low pH in the duodenum or passage of 
food into the duodenum in an effort to buffer the gas-
tric acids. Secretin was also structurally closely related 
to calcitonin (Kopic and Geibel 2013). Perhaps the 
lower secretin in the osteopenia implied less buffer-
ing of gastric acid, which could thereby inhibit calcium 
absorption.
For screening biomarkers, a variety of proteomic 
approaches have recently been performed to determine 
the protein composition in clinic. Most of these prot-
eomic technologies used mass spectrometric (MS) tech-
niques combined with several analytical techniques such 
as two-dimensional gel electrophoresis (2D-GE) or liquid 
chromatography (LC). While these approaches provided 
a large amount of data, they are generally very time-con-
suming and hence restrictive in the number of compara-
tive samples that can be analyzed.
MB-WCX with MALDI-TOF-MS technology is an 
approach that offers a unique platform for high-through-
put protein profiling of complex biological samples such 
as serum samples (Pusch and Kostrzewa 2005) (Cho et al. 
2013).
Furthermore, the cost of using this technology is low, 
and further protein identification can be performed from 
the eluted material without complex purification (Wieser 
et  al. 2012). Thus, magnetic beads-based enrichment 
approaches have the potential to capture and enrich low 
abundance, low molecular weight species (Whiteaker 
et al. 2007).
In addition, the advantage of MALDI-TOF-MS is the 
direct use of crude sample, large-scale, high-throughput, 
automated, and minimal sample requirements. MALDI-
TOF-MS not only can find a protein or biological mark-
ers, it also detected the combination of proteins existing 
in different forms (Gould et al. 2004).
In this study, all aspects of data processing such as sam-
ple inclusion and exclusion, serum collection, process-
ing and storage of serum, serum protein separation and 
purification, sample point target, MS acquisition, experi-
mental methods and parameter settings were optimized. 
Discovery researches in the clinical samples is better than 
in vitro and in vivo experiments.
In the aspect of data processing, data analysis software 
system was used to analysis data. The noise analysis was 
removed using undecimated discrete wavelet transform 
(UDWT) analysis (Aiazzi et  al. 2002; Fowler 2005). The 
model was established by SVM method. SVM were used 
to align and integrate hundreds of mass data points from 
large numbers of samples, and could be used to process 
many samples in parallel. This approach is sensitive and 
fast, these were features essential for clinical use. SVM 
exhibited many unique advantages in solving small sam-
ple, nonlinear and high dimensional pattern recognition 
problems and achieve the statistical theory of structural 
risk minimization principle. The application of these 
techniques obtained serum protein diagnostic model 
with high credibility.
Conclusions
This study provides a new serological method for dis-
covering serum protein markers to screen and diagnose 
osteopenia. This will be helpful in preventing and treat-
ing primary type I osteoporosis. Therefore, WCX mag-
netic beads and MALDI-TOF-MS can be used as a fast 
and cost-effective approach for serum samples discovery 
of predictive biomarkers of disease in osteopenia.
We speculate that the Secretin (SECR_HUMAN, 
P09683, Chain: 28–54, pI: 9.46, Mw: 3040) would be 
potential biomarker for forecasting osteopenia in post-
menopausal women.
However, there is still a gap between our findings and 
their application in clinical practice. Future controlled 
studies with larger sample sizes are required to deter-
mine the sensitivity and specificity of secretin in the diag-
nosis of osteoporosis. The further validation, function, 
interaction, and metabolic pathways of these proteins 
will be the future research. Moreover, Regarding to the 
MALDI-TOF-MS technology, for this technology does 
Table 5 Comparisons of  secretin concentrations in  the 
ELISA validation
Data shown are mean ± standard deviation
Groups Secretin concentra‑
tion (pg/mL)
t values P values
Normal bone mass 
(n = 40)
307.48 ± 74.68 t = 8.523 <0.05
Osteopenia (n = 40) 157.41 ± 82.62
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not identify protein or peptides sequence, the identities 
of peaks by TagIdent may not be the indeed protein or 
peptides. And therefore, the purification and identify of 
indeed protein or peptides were needed based on the 
standard sequencing approaches in the further.
Methods
Subjects and samples collection
Serum samples were collected from consenting patients 
(n = 20, 10 from postmenopausal women with osteope-
nia plus 10 from postmenopausal women with normal 
bone mass) enrolled from department of orthopedics, the 
Second Affiliated Hospital of Zhejiang Chinese Medicine 
University, from June 2013 and January 2014.
Diagnostic criteria
The diagnosis of osteopenia was based on the following 
recommended criteria by the WHO: Survey the lum-
bar vertebra normal position bone density by using dual 
energy X-ray absorptiometry (Unnanuntana et  al. 2010; 
Frost et al. 2012), T score −1 to −2.5 could be diagnosed 
as osteoporosis [T = the standard deviation of (measured 
value-peak bone mass)/(normal adult bone density)].
Inclusion criteria
Patients were included in the study based on the follow-
ing criteria: (1) they conform to the diagnostic criteria of 
osteoporosis; (2) they were postmenopausal women; (3) 
they were from 50 to 60 years old.
Exclusion criteria
Patients were excluded from the study based on the 
following criteria: (1) those that also had diseases that 
severely affect the metabolism of bone or calcium, such 
as diabetes, Cushing’s syndrome, function changing of 
the thyroid or parathyroid, osteomalacia, rheumatoid 
arthritis, multiple myeloma, bone tumor, osteoarthro-
sis, Paget’s disease, and osteogenesis imperfecta; (2) 
those that also had severe primary cardiac diseases, or 
diseases of the cerebral vessels or hematopoietic system; 
(3) those that also had severe liver function or renal 
insufficiencies; (4) those taking drugs within the past 
6 months that affect bone metabolism, such as estrogen, 
steroid hormones, calcitonin, parathyroid hormones, 
bisphosphonates, fluoride, vitamin D, anticonvulsant 
drugs, and diuretics; (5) those who had a medical his-
tory of mental illness; and (6) patients with Alzheimer’s 
disease.
Ethical review
This study was approved by the local Ethics Commit-
tee of The Second Affiliated Hospital of Zhejiang Chi-
nese Medicine University. The patients and volunteers 
provided written informed consent for their participation 
before they enrolled in this study.
Sample collection and preparation
The blood samples (5  ml) were collected in the morn-
ing and allowed to clot at room temperature for up to 
1–2 h. The samples were then centrifuged at 4 °C for ten 
min at 3000 rpm (in 943×g). The serum were frozen and 
stored at −80 °C for future analysis. The length of cryo-
preservation period for each serum sample was less than 
6 months.
Weak cation magnetic separation technology analysis
Magnetic beads-based weak cation exchange chroma-
tography (MB-WCX) (Bruker Daltonics, Germany) was 
used for peptidome separation of samples. We prepared 
a 200-μL sample tube of thoroughly mixed weak cation 
magnetic suspension by adding 10  μL magnetic beads 
binding buffer, 10  μL magnetic beads suspension, and 
5 μL serum, mixing at least five times using the sampling 
gun, and standing at room temperature for 5 min. We put 
the sample tube into the magnetic separator, maintained 
the magnetic field for 1  min, used the sampling gun to 
absorb the liquid after separation of the magnetic beads 
and liquid, and added to the sample tube 100 μL magnetic 
beads cleaning buffer. We then moved the sample tube 
ten times between the two adjacent holes of the mag-
netic separator, left to stand, and used the sample gun to 
absorb the supernatant again after magnetic beads adher-
ence. We repeated the cleaning process twice. We then 
took down the sample tube from the magnetic separator, 
added 5 μL magnetic beads elution buffer to the sample 
tube, and repeated the pipetting. We put the sample tube 
into the magnetic separator and let it stand for 2  min, 
transferred the supernatant to a clean 0.5-mL sample 
tube when the magnetic beads were completely adhered, 
then added 5  μL magnetic beads stabilizing buffer. The 
eluate was then ready for spotting onto MALDI-TOF MS 
targets and measured.
Anchor chip spotting
1  μL eluted sample was spotted onto a MALDI-TOF 
AnchorChipTM target (600  μm anchor diameter) 
and air-drying at room temperature, then 1  μL matrix 
(0.3  mg/mL HCCA, 50  %ACN, 2  %TFA) was spotted 
onto MALDI-TOF AnchorChipTM target.
MALDI‑TOF MS
AnchorChipTM target was placed into the Microflex 
mass spectrometer (Bruker Daltonics). Samples were 
detected after calibration of the instrument by ClinProt 
standard (Bruker Daltonics). MALDI-TOF MS param-
eters are detailed in Additional file 1.
Page 8 of 9He et al. SpringerPlus  (2016) 5:679 
Detection data analysis
The Zhejiang University-ProteinChip data analysis system 
(ZJU-PDAS) software, designed at Zhejiang University 
Cancer Institute, was used to analyze the raw data (Shi 
et  al. 2014). The process was as follows. (1) The original 
spectrum was uploaded to the server to map data for pro-
tein analysis, and to process homogeneous data. (2) We 
removed the mass-to-charge ratio (m/z) of raw data below 
peak 2000, used the UDWT analysis method to remove 
the noise caused by the mass spectrometer itself, and used 
the amended data after the removal of the baseline noise 
spectrum and correction of the molecular weight values 
map. (3) We identified the protein charge ratio peaks with 
local minima, and filtration peak signal-to-noise ratios of 
less than 3. The differences in m/z between each sample of 
<0.3 % of the peak were clustered together. After cluster-
ing, peaks appeared only in the sample in less than 10 % 
removed. (4) To find the peak intensity in the respective 
sample treated as uniform. (5) After pretreatment, we fil-
tered out protein charge ratio peaks using the Wilcoxon 
rank sum test, and screened differential protein peaks 
(P < 0.05). (6) We screened a random combination of dif-
ferent proteins, and used a genetic arithmetic model and 
the support vector machine (SVM) computing model to 
establish serum protein fingerprints.
For the SVM, we used the radial basis function, a 
gamma value of 0.6, and the penalty function (C) was 
set to 19. The highest elected combinations were used 
to build the SVM model to predict the Youden index. 
Because the final candidate signs matter, we used the 
leave-one-assessment model to predict the effect of an 
established law and the final results were cross-validated.
ZJU-PDAS specific parameters of analysis were 
detailed in Additional file 2.
Identities of the two differential peaks suggested 
by TagIdent
Using TagIdent tool (Washam et al. 2013; Liu et al. 2012) 
network software (http://web.expasy.org/tagident/), 
molecular weight (Mw) range was set to 0.3  %, Isoelec-
tric point (PI) range value was set to min = 4, max = 14. 
Checked for protein sequences with cysteines oxidized 
(–SS–); Organism name: homo sapiens; Tagging: Display 
only the sequences matching the tag, Displayed the pre-
dicted N-terminal sequence, Databases on UniProtKB/
Swiss-Pro. Proteins as candidate were selected by the 
most similar molecular weight.
Immunoassay for quantification of the candidate 
biomarker secretin
After the identity was suggested by TagIdent, ELISA 
was used to detect the levels in sera. Secretin levels were 
measured in the serum samples using an ELISA 96-well 
plate for secretin (CEB075Hu, Cloud-Clone Corp., Hou-
ston, USA). The serum samples were diluted 1:1 with a 
0.01 mol/L PBS (PH 7.0–7.2) according to the manufac-
turer’s instructions and analyzed on a RT-2100C micro 
plate reader (Rayto, USA) at a wavelength of 450  nm 
according to the manufacturer’s instructions.
Statistical analysis
All MALDI-TOF-MS spectrum were analyzed by ZJU-
PDAS software to detect the peak intensities of interest, 
and to compile the peaks across the spectrum obtained 
from serum samples. All statistical comparisons were 
done by SPSS software version 13.0 (SPSS Inc., USA). The 
comparison of the age, weight, height, duration of meno-
pause, and comparisons of secretin concentrations was 
done by t test, test level of α = 0.05. The Wilcoxon rank 
sum test (test level of α = 0.05) was used to compare fea-
tures. P values <0.05 were considered statistically signifi-
cant. Genetic algorithm (GA) (Deb et al. 2002), Support 
vector machine (SVM) (Weston et al. 2000), and Youden 
Index (Schisterman et  al. 2005) methods were used to 
establish the diagnosis model and predict the candidate 
markers. The model was verified by leaving-one-out cross 
validation test (Wuebker et al. 2010).
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